Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(18):1331; doi:10.1093/jnci/djn269
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/18/1331    most recent
djn269v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gurwitz, D.
Right arrow Articles by Newman, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gurwitz, D.
Right arrow Articles by Newman, W.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

David Gurwitz, William Newman

Affiliations of authors: Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv Israel (DG); Department of Medical Genetics, University of Manchester, United Kingdom (WN)

Correspondence to: Dr David Gurwitz, PhD, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel (e-mail: gurwitz@post.tau.ac.il).

The first 10% of the full text of this article appears below.

The modeling analysis of the Breast International Group 1–98 (BIG1-98) trial presented by Puglia et al. (1) provides an important impetus to further studies of tamoxifen pharmacogenetics. However, it is important to note that their analysis focused solely on the CYP2D6*4 allele. Although CYP2D6*4 is the allele most frequently associated with poor tamoxifen . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Rinaa S. Punglia, Harold J. Burstein, Eric P. Winer, and Jane C. Weeks
J Natl Cancer Inst 2008 100: 1332-1333. [Extract] [Full Text] [PDF]

Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Daniel F. Hayes, Vered Stearns, James Rae, and David Flockhart
J Natl Cancer Inst 2008 100: 1333-1334. [Extract] [Full Text] [PDF]